For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230605:nRSE6994Ba&default-theme=true
RNS Number : 6994B Oncimmune Holdings PLC 05 June 2023
5 June 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive
Officer, today purchased 48,370 ordinary shares of £0.01 each in the Company
("Ordinary Shares") at a price of £0.206533 per share.
Following this transaction, Dr Hill has a total interest in the Company of
122,242 Ordinary Shares, representing approximately 0.17 per cent. of the
Company's issued share capital of 74,142,147.
In addition, Dr Hill holds options over a total of 3,615,862 Ordinary Shares,
representing approximately 4.88 per cent. of the Company's issued share
capital.
This announcement, including the notification below, is made in accordance
with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging
managerial responsibilities and persons closely associated with them:
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Adam Mark Hill
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oncimmune Holdings plc
b) LEI 213800HCYIWT6YPI1I02
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of £0.01 each
Identification code ISIN: GB00BYQ94H38
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£0.206533 48,370
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 5 June 2023
f) Place of the transaction London Stock Exchange, AIMX
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.
For more information, visit www.oncimmune.com (http://www.oncimmune.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZELFBXQLEBBV